# Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.

> **NCT05962606** · PHASE2 · COMPLETED · sponsor: **Aptarion Biotech AG** · enrollment: 150 (actual)

## Conditions studied

- Community-acquired Pneumonia

## Interventions

- **DRUG:** AON-D21
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05962606
- **Lead sponsor:** Aptarion Biotech AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-02
- **Primary completion:** 2026-03-16
- **Final completion:** 2026-03-16
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05962606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05962606, "Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT05962606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*